Should cetuximab replace cisplatin for definitive chemoradiotherapy in locally advanced head and neck cancer?

Journal of Clinical Oncology

Volumn 31, Issue 2, 2013, Pages 287-288

  Riaz, Nadeem ^a   Sherman, Eric J ^a   Fury, Matthew ^a   Lee, Nancy ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; PANITUMUMAB;

CANCER SURVIVAL; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; FAILURE FREE SURVIVAL; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; LETTER; LOCALLY ADVANCED HEAD AND NECK CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

ANTIBODIES, MONOCLONAL; CHEMORADIOTHERAPY; CISPLATIN; HEAD AND NECK NEOPLASMS; HUMANS; RETROSPECTIVE STUDIES;

EID: 84872482001     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.9049     Document Type: Letter

References (17)

1. Pignon JP, le Maitre A, Maillard E, et al: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4-14, 2009
2. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006 (Pubitemid 43209104)
3. Curran D, Giralt J, Harari PM, et al: Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 25:2191-2197, 2007 (Pubitemid 46954642)
4. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21-28, 2010
5. Koutcher L, Sherman E, Fury M, et al: Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 81:915-922, 2011
6. Koutcher LD, Sherman EJ, Carlson D, et al: Cisplatin (CDDP) and radiation (RT) versus cetuximab (C) and RT in the context of human papillomavirus (HPV) and P16 in the treatment of locally advanced head and neck cancer (LAHNC). American Society for Radiation Oncology Annual Meeting, San Diego, CA, October 31-November 4, 2010 (abstr 133)
7. Shapiro LQ, Sherman EJ, Koutcher L, et al: Efficacy of concurrent cetuximab (C225) versus 5-fluorouracil/carboplatin (5FU/CBDCA) or cisplatin (CDDP) with intensity-modulated radiation therapy (IMRT) for locally advanced head and neck cancer (LAHNSCC). J Clin Oncol 30:365s, 2012 (suppl 15; abstr 5537)
8. Lefebvre J, Pointreau Y, Rolland F, et al: Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Results of the randomized phase II TREMPLIN study. J Clin Oncol 30:360s, 2012 (suppl 15; abstr 5501)
9. Ley J, Mehan P, Wildes TM, et al: Concurrent cisplatin vs. cetuximab with definitive radiation therapy (RT) for head and neck squamous cell carcinoma (HNSCC): A retrospective comparison. Multidisciplinary Head and Neck Cancer Symposium, Phoenix, AZ, January 26-28, 2012 (abstr 163)
10. Caudell JJ, Sawrie SM, Spencer SA, et al: Locoregionally advanced head and neck cancer treated with primary radiotherapy: A comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys 71:676-681, 2008
11. Levy AR, Johnston KM, Sambrook J, et al: Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck. Curr Med Res Opin 27:2253-2259, 2011
12. Ang KK, Zhang QE, Rosenthal DI, et al: A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 30:360s, 2011 (suppl 15; abstr 5500)
13. Stewart JS, Cohen EE, Licitra L, et al: Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 27:1864-1871, 2009
14. Licitra L, Mesia R, Rivera F, et al: Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol 22:1078-1087, 2011
15. Cohen EE, Lingen MW, Martin LE, et al: Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 11:8105-8108, 2005
16. Stoehlmacher-Williams J, Villanueva C, Foa P, et al: Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (+) recurrent/ metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Analysis of the global phase III SPECTRUM trial. J Clin Oncol 30:357s, 2012 (suppl 15; abstr 5504)
17. Seiwert T, Fayette J, Cupissol D, et al: A randomized, open-label, phase II study of afatinib (BIBW 2992) versus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: Final data. Presented at the Multidisciplinary Head and Neck Cancer Symposium, Phoenix, AZ, January 26, 2012